C
Caroline A. Nebhan
Researcher at Vanderbilt University Medical Center
Publications - 32
Citations - 2965
Caroline A. Nebhan is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 19 publications receiving 2250 citations. Previous affiliations of Caroline A. Nebhan include Vanderbilt University & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren Cross,Susan Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth D Hughes,Amar Rahi,Vivien Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham Richmond,Mireille Cantarini,Dong Wan Kim,Malcolm R Ranson,William Pao +25 more
TL;DR: A novel structurally distinct third-generation EGFR TKI that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR is reported.
Journal ArticleDOI
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Ken Takezawa,Valentina Pirazzoli,Maria E. Arcila,Caroline A. Nebhan,Xiaoling Song,Elisa de Stanchina,Kadoaki Ohashi,Yelena Y. Janjigian,Paula J. Spitzler,Mary Ann Melnick,G. J. Riely,Mark G. Kris,Vincent A. Miller,Marc Ladanyi,Katerina Politi,William Pao +15 more
TL;DR: It is shown in vitro and in vivo that afatinib plus cetuximab significantly inhibits HER2 phosphorylation, and this results reveal a previously unrecognized mechanism of resistance to EGFR-TKIs and provide a rationale to assess the status and possibly target HER2 in EG FR-mutant tumors with acquired resistance toEGFR- TKIs.
Journal ArticleDOI
N-WASP and the Arp2/3 Complex Are Critical Regulators of Actin in the Development of Dendritic Spines and Synapses
Adam M. Wegner,Caroline A. Nebhan,Lan Hu,Devi Majumdar,Kristen M. Meier,Alissa M. Weaver,Donna J. Webb +6 more
TL;DR: Neural Wiskott-Aldrich syndrome protein (N-WASP) regulates the formation of dendritic spines and synapses in hippocampal neurons and Arp2/3-mediated branching of actin could be a mechanism by which dendrite spine heads enlarge and subsequently mature.
Journal ArticleDOI
Immune-checkpoint inhibitors: long-term implications of toxicity
TL;DR: In this paper , the authors describe the current evidence for chronic immune toxicities and the long-term implications of these effects for patients receiving immune-checkpoint inhibitors (ICIs).
Journal ArticleDOI
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1
Valentina Pirazzoli,Caroline A. Nebhan,Xiaoling Song,Anna Wurtz,Zenta Walther,Guoping Cai,Zhongming Zhao,Peilin Jia,Elisa de Stanchina,Erik M. Shapiro,Molly Gale,Ruonan Yin,Leora Horn,David P. Carbone,Philip J. Stephens,Vincent A. Miller,Scott N. Gettinger,William Pao,Katerina Politi +18 more
TL;DR: Findings pinpoint enhanced mTORC1 activation as a mechanism of resistance to afatinib plus cetuximab and identify genomic mechanisms that lead to activation of this pathway, revealing a potential therapeutic strategy for treating patients with resistance to these drugs.